Home
About
Share This
Set as HomepageTrisenox
TRISENOX®
4 5 Introduction You have been given this booklet to learn more about a new drug called. After reading this booklet, you should know: n What TRISENOX ® is and how it works, n The possible side effects of TRISENOX ®, and n What the basic types of TRISENOX ®-based treatment are and how they are ...
WARNING Experienced Physician and Institution: TRISENOX ...
TRISENOX™ Rx only 1 (arsenic trioxide) injection 2 For Intravenous Use Only 3 10 mg/10 mL (1 mg/mL) ampule 4 WARNING Experienced Physician and Institution: TRISENOX™ (arsenic trioxide) injection should be administered under the supervision of a physician who is experienced in the management ...
DEPARTMENT OF HEALTH & HUMAN SERVICES
• “TRISENOX exhibited low rates of grades 3 and 4 myelosuppression [4,5]” • “There was no incidence of alopecia [4,5]” • “QT prolongation is an expected but manageable event
APL Differentiation Syndrome
1 TRISENOX™ Rx only 2 (arsenic trioxide) injection 3 For Intravenous Use Only 4 10 mg/10 mL (1 mg/mL) ampule WARNING Experienced Physician and Institution: TRISENOX™ (arsenic trioxide) injection should
IMPORTANT PRESCRIBING INFORMATION
The arsenic trioxide used in the reported study was not Cell Therapeutics'Trisenox ™ (arsenic trioxide) injection. QT prolongation is a well described toxic effect of arsenic trioxide.
For Intravenous Use Only 10 mg/10 mL (1mg/mL) ampule
For Intravenous Use Only 10 mg/10 mL (1mg/mL) ampule Rx only WARNING Experienced Physician and Institution: TRISENOX (arsenic trioxide) injection should be administered under the supervision of a physician who is experienced in the management of patients with acute leukemia.
For Intravenous Use Only 10 mg/10 mL (1 mg/mL) ampule
WARNING Experienced Physician and Institution: TRISENOX (arsenic trioxide) injection should be administered under the supervision of a physician who is experienced in the management of patients with acute leukemia.
Abstract Submittal Guidelines
Trisenox (TX) therapy has recently been approved by FDA based on its effectiveness in providing for a complete remission in de novo and relapsed APL patients.
What is the material and what do I need to know in an emergency?
TRISENOX™ MSDS PAGE 1 OF 12 MATERIAL SAFETY DATA SHEET Prepared to U.S. OSHA, CMA, ANSI, Canadian WHMIS and European Community Standards PART I What is the material and what do I need to know in an emergency?
Overview and Frontier for the Development of Metallopharmaceu ...
Journal of Health Science , 56 (2) 129-143 (2010) 129 — Review — Overview and Frontier for the Development of Metallopharmaceu tics Hiromu Sakurai ∗ Laboratory of Pharmacoanalytic al Chemistry, Department of Physical Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Suzuka ...
